Skip to main content
. 2021 Apr 2;10(1):664–676. doi: 10.1080/22221751.2021.1905488

Figure 4.

Figure 4.

Cross-reactive HCoV-OC43 antibody titres correlate with disease severity in COVID-19 patients. (A) Dynamic changes of SARS-CoV-2 S-IgG levels in mild and severe COVID-19 patients. (B) HCoV-OC43 S-IgG levels in COVID-19 patients in different age groups over time post symptom onset (PSO). (C) The correlation between the HCoV-OC43 S-IgG titres and disease severity (mild and severe) in different age groups. (D) The correlation between HCoV-OC43 S-IgG titres and clinical outcome (survivor and non-survivor) in patients aged 60–85 yearsat days 1–10 PSO. (E) The correlation between HCoV-OC43 N-IgG titres and disease severity (mild and severe) in different age groups. (F) The correlation between HCoV-OC43 N-IgG titres and clinical outcome (survivor and non-survivor) in patients aged 60–85 years at days 1–10 PSO. All the antibody titres were analysed using ELISA assays and shown as mean with SD. Non-parametric Mann–Whitney test was used for comparison of antibody titres. The correlation were assessed by Spearman’s rank correlation test.